Cargando…

Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand

Detalles Bibliográficos
Autores principales:	Jiang, Hong, Dwyer, Karen, Bover, Laura, Lang, Frederick, Gomez-Manzano, Candelaria, Fueyo, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649452/ http://dx.doi.org/10.1186/2051-1426-3-S2-P337

Ejemplares similares

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
por: Jiang, Hong, et al.
Publicado: (2014)

GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory
por: Rivera-Molina, Yisel, et al.
Publicado: (2019)

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
por: Kleijn, Anne, et al.
Publicado: (2014)

IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS
por: Labiano, Sara, et al.
Publicado: (2021)

Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
por: Jiang, Hong, et al.
Publicado: (2023)

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection
por: González-Morales, Andrea, et al.
Publicado: (2018)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
por: Martínez-Vélez, Naiara, et al.
Publicado: (2019)

IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION
por: Laspidea, Virginia, et al.
Publicado: (2021)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

THER-02. EVALUATION OF THE ONCOLYTIC VIRUS DELTA24-RGD AS AN ANTI-TUMOR AGENT IN PRECLINICAL MODELS OF LOCALIZED AND DISSEMINATED AT/RT
por: Garcia-Moure, Marc, et al.
Publicado: (2020)

Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models
por: Martinez-Velez, Naiara, et al.
Publicado: (2019)

A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014)

DIPG-10. DELTA-24-RGDOX PROMOTES ANTITUMOR IMMUNE RESPONSE IN DMG MODELS
por: Laspidea, Virginia, et al.
Publicado: (2023)

Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus
por: Al-Zaher, Ahmed Abdullah, et al.
Publicado: (2018)

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
por: Ylösmäki, Erkko, et al.
Publicado: (2021)

EPCT-04. RESULTS OF A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 WITH RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Garcia-Moure, Marc, et al.
Publicado: (2021)

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
por: Martinez-Velez, Naiara, et al.
Publicado: (2022)

A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017)

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
por: Shin, Dong Ho, et al.
Publicado: (2021)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL
por: Iñigo-Marco, Ignacio, et al.
Publicado: (2020)

C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy
por: Klein, SR, et al.
Publicado: (2015)

Oncolytic adenoviruses: A thorny path to glioma cure
por: Ulasov, I.V., et al.
Publicado: (2014)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
por: Laspidea, Virginia, et al.
Publicado: (2022)

THER-01. AWAKING THE IMMUNE SYSTEM WITH AN IMMUNO-ONCOLYTIC VIRUS AS A THERAPEUTIC STRATEGY FOR DIPGs
por: Laspidea, Virginia, et al.
Publicado: (2020)

RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells
por: Yang, Y, et al.
Publicado: (2015)

Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma
por: Kiyokawa, Juri, et al.
Publicado: (2019)

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry
por: Nguyen, Teresa T, et al.
Publicado: (2022)

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity
por: Kleijn, Anne, et al.
Publicado: (2017)

New pathways in immune stimulation: targeting OX40
por: Alves Costa Silva, Carolina, et al.
Publicado: (2020)

Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors
por: Varela-Guruceaga, Maider, et al.
Publicado: (2018)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
por: Hu, Mingming, et al.
Publicado: (2023)

OX40: a win–win path to tumor immunity
por: Sedwick, Caitlin
Publicado: (2008)

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_2d4d6769lbs1jdgn3rsn1ls3va